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Background: The present study was aimed to investigate lipid profile in rela-
tion to anthropometric indices and insulin resistance in overweight or obese 
women with polycystic ovary syndrome (PCOS).  
Methods: In this cross-sectional study, lipid profile and anthropometric indi-
ces including body mass index (BMI), waist and hip circumference, waist to 
hip ratio (WHR), and waist to height ratio (WHtR) were evaluated in 63 over-
weight or obese PCOS patients subdivided into insulin-resistant (IR) and non-
insulin-resistant (NIR) groups. IR was defined as homeostasis model of insulin 
resistance (HOMA-IR) ≥3.8. 
Results: Fasting insulin concentration and HOMA-IR were higher (P<0.001) 
and high-density lipoprotein cholesterol (P=0.012) was lower in IR group. All 
of the anthropometric measures other than WHR and BMI showed significant 
correlations with several lipid parameters. Amongst, WHtR showed the 
strongest correlation with total cholesterol (TC) (r=0.37; P=0.004) and low-
density lipoprotein cholesterol (LDL-C) (r=0.33; P=0.011) in the whole PCOS 
patients.  
Conclusion: Anthropometric characteristics (especially BMI and hip circum-
ference) are more important parameters correlated to lipid profile than IR in 
overweight or obesePCOS patients, confirming the importance of early treat-
ment of obesity to prevent dyslipidemia in the future. 
 
 
Article history: 
Received: Jul 15 2013 
Accepted: Sep 02 2013 
e-published: Dec 31 2013 
 
 
Keywords: 
Lipid profile, 
Dyslipidemia,  
Insulin resistance, 
Obesity,  
Polycystic ovary syndrome 
 
 
*Corresponding Author: 
MehranghizEbrahimi-Mameghani 
Tel: +984113357581;  
e-mail: 
ebrahimimamagani@tbzmed.ac.ir 
 
 
 
 
 
 
 
 
 
 
Introduction  
 
Polycystic ovary syndrome (PCOS) is a 
heterogeneous gynecological disorder that 
includes oligo/anovulation, clinical or bio-
chemical hyperandrogenism and/or poly-
cystic ovaries. It affects 5% to 10% of wom-
en at reproductive age
1. PCOS is associated 
with a wide range of endocrine and metabol-
ic abnormalities including obesity, insulin re-
sistance, and metabolic syndrome (MetS)
2. 
Insulin resistance (IR) is considered as an 
important factor in the pathogenesis of 
PCOS which affects the long-term health
3. 
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IR plays a significant role in the develop-
ment of dyslipidemia. About 70% of PCOS 
women have at least one abnormal lipid 
constituent
4. Obese women with PCOS are 
more prone to dyslipidemia, particularly ele-
vated triglycerides (TG) and decreased high-
density lipoprotein cholesterol (HDL-C)
5. 
However, much of the atherogenic lipopro-
tein pattern in PCOS has been related to 
obesity
6.Cibula et al. showed the effect of 
obesity on lipid profile and hyperlipopro-
teinemia in PCOS women
7. Obesity, rather 
than the pattern of menstrual cycle deter-
mines lipid profile and insulinemia in aging 
PCOS women
8. In addition, regional distri-
bution of body fat deposit plays a key role in 
plasma lipids and cardiovascular risk
9. Re-
cently, it was reported that an abnormal 
postprandial lipid pattern is a trait of ab-
dominal obesity even without fasting hyper-
triglyceridemia
10. Therefore, obesity likely 
plays a significant role in the pathogenesis of 
the syndrome
11.  
About half of PCOS patients have obe-
sity
12, especially central obesity that worsens 
its phenotype
13. Women with PCOS have a 
similar amount of total and trunk fat, but a 
higher quantity of central abdominal fat 
compared with weight-matched healthy 
women
14. Indeed, central fat excess may be 
associated with insulin resistance and low-
grade chronic inflammation
14 and with met-
abolic dysfunction in PCOS women
15. In 
addition, excess intra-abdominal fat is asso-
ciated with greater risk of obesity-related 
morbidity than is overall adiposity
16. Thus, 
measurements of waist circumference and 
waist to hip ratio (WHR) have been sug-
gested as alternatives to body mass index 
(BMI). Several studies on adults have re-
ported a stronger positive association be-
tween cardiovascular risk factors such as 
hypertension, lipid and glucose concent-
rations with abdominal adiposity (measured 
by waist circumference (WC) or WHR) than 
with overall adiposity (as measured by BMI)
 
17-18, although BMI has also been reported as 
being one of the most important risk factors 
for type 2 diabetes
19. 
Women with PCOS have a 7.4-fold rela-
tive risk for myocardial infarction because of 
the prevalence of dyslipidemia, glucose in-
tolerance, insulin resistance, hypertension
20, 
and central obesity
21.  
Concerning the well-proven relationship 
between insulinresistance and obesity
11, the 
relative contribution of these twofactors to 
lipid profile in PCOS seems to be pivotal to 
better understand this heterogeneous syn-
drome.  
The present study was aimed to investi-
gate the influence of anthropometric indices 
and insulin resistance on lipid profile in 
overweight or obese PCOS patients subdi-
vided into insulin-resistant (IR) and nonin-
sulin-resistant (NIR) groups. 
 
Materials and Methods 
 
Patient population 
This cross-sectional study was carried out 
from January 2011 to August 2012 in Gyne-
cology and Endocrinology Outpatient Clin-
ics of Tabriz University of Medical Sciences, 
Iran. The study included 63 overweight or 
obese patients diagnosed as PCOS. The re-
search protocol was approved by the Ethics 
Committee of the University (ethical 
code=906). Written informed consent was 
obtained from all the participants. 
The diagnosis of PCOS was confirmed 
according to the revised Rotterdam criteria
22, 
in which the presence of any two out of the 
three following criteria were required: (1) Ol-
igo- and/or anovulation (<8 menstrual peri-
ods per year)
 23, (2) clinical and/or biochemi-
cal signs of hyperandrogenism, including hir-
sutism (Ferriman-Gallwey score> 8) and (3) 
polycystic ovaries on sonography (i.e., at 
least 1 ovary containing 12 or more periph-
eral follicles measuring 2–9 mm in diameter 
and/or ovarian volume of at least 10 mL)
24 
and exclusion of other etiologies (congenital 
adrenal hyperplasia, androgen-secreting tu-
mors, and Cushing's syndrome). Vaginal or 
transabdominal pelvic sonography, as ap-
propriate, was performed only on patients 
who did not fulfill the diagnostic criteria. 
The inclusion criteria were any PCOS pa-Health Promotion Perspectives, Vol. 3, No. 2, 2013; P: 206-216 
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tient diagnosed by the above mentioned cri-
teria with age range between 17 to 37 years 
old, BMI range between 25 to 39 kg/m
2, and 
taking no medicines at least 2 months before 
the study. Any patient with a disease affect-
ing metabolic parameters including hypogly-
cemia, Diabetes Mellitus, Cushing's syn-
drome, androgen secreting tumors or con-
genital adrenal hyperplasia, hy-
perparathyroidism, hyperprolactinemia, thy-
roid disorders, hypertension and etc. were 
excluded from the study. Patients taking 
drugs or any dietary supplements within the 
two months before the study were also ex-
cluded. Indeed, history of being on a special 
diet such as weight loss diet during the 6 
months before the onset of the study was re-
garded as excluded criteria.  
The obtained data for medical history in-
cluded questions about age, intake of drugs, 
smoking and alcohol consumption. Dietary 
intake was measured using a 3-day food rec-
ord. Blood pressure (BP) was measured after a 
10-min rest period using digital automatic 
blood pressure monitor, Omron, Japan. Sys-
tolic BP above 140 mmHg and diastolic BP 
above 90 mmHg were regarded as hyperten-
sion
25. Subjects were weighed to within 100 g 
in light clothing without shoes. Height was 
measured to the nearest 0.1 cm using a wall-
mounted stadiometer. BMI was calculated as 
weight (kg) divided by the square of height 
(m). For further analysis, the patients were also 
subdivided into 2 subgroups of BMI: the 
overweight group (BMI range, 25-29.9 kg/m
2) 
or the obese group (BMI≥30 kg/m
2)
26. Lipid 
profile was also compared between these two 
subgroups. Waist circumference (WC) (cm) 
was measured at a level midway between the 
lower rib margin and iliac crest
27 and hip cir-
cumference (HC) at the widest point between 
the iliac crest and buttock
21. The circumfer-
ences were measured in a standing position 
and to the nearest 1 mm. The waist circumfer-
ence was divided by the hip circumference as 
well as by height to give waist to hip ratio 
(WHR) and waist to height (WHtR) ratios, 
respectively. 
The standard oral glucose tolerance test 
(OGTT) was performed two hours after ad-
ministration of 75 gram glucose for all the 
patients
28. The homeostasis model of insulin 
resistance (HOMA-IR) was calculated as 
[fasting plasma glucose concentration 
(mmol/L)×fa-sting serum insulin concentra-
tion  (µU/mL)/-22.5]
29.IR was defined as 
HOMA-IR value  ≥3.8  (30). Impaired glu-
cose tolerance (IGT) was defined as an ele-
vated fasting glucose 
(110mg/dL≤G0≤125mg/dL) or an ele-
vated 2-hour glucose (140mg/dL ≤ G120-
≤199mg/dL)
  30. Diabetes was defined as 
fasting plasma glucose above 126 mg/dl
31. 
Hyperandrogenemia was considered as ei-
ther  serum  testosterone  level  above  2.08 
nmol/l and/or serum dehydroe-
piandrosteronesulphate  (DHEAS) level 
above  7800  nmol/l
32. Increased serum 17-
OHP was defined in levels above 2 ng/ml to 
exclude congenital adrenal hyperplasia
33. 
 
Laboratory measurements  
After a 12-hour overnight fast, 10 ml blood 
was obtained in the follicular phase of the 
menstrual cycle (i.e. serum progesterone level 
lower than 2.5 ng/ml)
 34. In terms of high pro-
gesterone level, the whole measurements were 
repeated after one or two weeks. The whole 
blood samples were centrifuged at 3000 rpm 
for 5 min. The samples were analyzed either 
immediately or during the first week after con-
servation at -20 °C.  
Serum glucose, total cholesterol (TC), TG, 
and HDL were analyzed using the standard 
enzymatic method (Pars Azmoon kit, Pars 
Azmoon Inc., Tehran, Iran) (glucose: CV in-
ter-assay=0.90%, TC: CV inter-assay=1.1%, 
TG: CV inter-assay=1.6%, and HDL: CV in-
ter-assay=1.8%).  LDL-C was calculated with 
the Friedewald(35)  Formula: LDL= [TC]-
[HDL]-[TG]/5.0 (mg/dL). DHEAS (DRG 
Instruments GmbH, Germany, CV inter-as-
say=4.8%),  and  plasma  insulin  levels  (Liai-
son®; DiaSorin S.P.A., Saluggia, Vercelli, Italy, 
CV inter-assay=3.9%) were measured  using 
chemiluminescence methods. 
 
Statistical analysis 
  The Kolmogorov-Smirnov test was 
used to check for the normality of the data; 
all data were normally distributed. Data were Saghafi-Aslet al.: Lipid Profile In Relation To Anthropometric Indices… 
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expressed as mean±SD for continuous vari-
ables. Independent samples t-test was used 
to compare continuous variables. Correla-
tions between lipid profile and anthropo-
metric indices were examined using Pear-
son’s correlation coefficients. Partial corre-
lations were performed to determine these 
associations after controlling  for age and 
serum DHEAS level as confounders. 
P<0.05 was set as significant. 
 
Results   
 
Thirty-six percent of PCOS patients with 
overweight or obesity had HOMA-IR≥3.8 
and formed insulin-resistant group. Further-
more, only 5 out of 63 PCOS patients had 
glucose intolerance (BS2h=142-215 mg/dl); 
however, none were diabetic. None of the 
PCOS patients were taking drugs at least 2 
months before the study. Further, nobody 
smoked or consumed alcohol before or during 
the study. In addition, none of the patients 
were hypertensive. The mean age and BMI of 
the patients were 26.9±5.7 years and 31.4±3.8 
kg/m
2, respectively. General characteristics 
and anthropometric indices of the patients in 
the IR and the NIR groups are shown in Table 
1.The IR and NIR groups did not differ in 
terms of age and systolic or diastolic blood 
pressure (Table1). There was no significant 
difference in energy intake, using a 3-day food 
record, between the two groups (2382 in the 
IR vs. 2355 kcal/day in the NIR group). The 
mean BMI was similar between the two 
groups (32.27±3.46in the IR vs.  30.91±3.88 
kg/m
2 in the NIR group, Table 1; P=0.175). 
More than half of the patients were simi-
larly hyperandrogenic in the IR and NIR 
groups (P=0.55). Around 80% of the IR and 
NIR groups were hirsute. The two groups had 
similar oligo/anovulation pattern (95% in both 
groups).  
 
0
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IR Mean±SD
NIR Mean±SD
 
 
Fig. 1: Mean (SD) of Lipid profile between IR- 
and NIR- PCOS patients (* P<0.05) 
TC=Total cholesterol; HDL-C=High-density 
lipoprotein cholesterol; LDL-C=Low-density 
lipoprotein cholesterol 
 
Obesity was significantly more prevalent in the 
IR compared to the NIR group (77% vs. 50%, 
P=0.038).  Waist  circumference  was  non-sig-
nificantly higher in the IR group compared 
with the NIR group (P=0.072). Fasting insulin 
concentration and HOMA-IR were signifi-
cantly higher (P<0.001) in the IR compared 
with the NIR group (Table 1).  
 
Table 1: General characteristics and anthropometric indices between IR and NIR PCOS women 
 
Variables  IR group (n=23) 
Mean±SD 
NIR group (n=40) 
Mean±SD 
P-value 
Age (yr)   26.96±6.58  26.80±5.29  0.918 
Blood pressure (mmHg)       
  Systolic   113.17±7.73  111.12±9.34  0.443 
  Diastolic   76.35±9.70  72.50±9.43  0.184 
Energy (kcal/day)  2382.17±530  2355.91±655  0.630 
Fasting insulin (µU/mL)  23.19±7.44  12.72±6.032  <0.001 
HOMAIR  5.18±1.53  2.60±0.76  <0.001 
BMI (kg/m2)  32.27±3.46  30.91±3.88  0.175 
WC (cm)  96.20±7.67  93.19±8.88  0.205 
HC (cm)  108.35±6.70  104.34±9.46  0.067 
WHR  0.88±0.03  0.89±0.04  0.577 
WHtR  0.612±0.054  0.589±0.062  0.184 Health Promotion Perspectives, Vol. 3, No. 2, 2013; P: 206-216 
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Table 2: Frequency of lipid abnormalities in the whole PCOS women and between the IR and NIR 
groups 
 
Variables   All patients 
(n=63) 
IR group 
(n=23) 
NIR group 
(n=40) 
P- value 
TG (mg/dl)         
 ≥150   25 (39.7)  10 (43.5)  15 (37.5)  0.643 
<150   38 (60.3)  13 (56.5)  25 (62.5)   
TC (mg/dl)         
 ≥200   24 (38.1)  10 (43.5)  14 (35)  0.508 
<200   39 (61.9)  13 (56.5)  26 (65)   
HDL-C (mg/dl)         
<50   45 (73)  19 (82.6)  26 (65)  0.139 
≥50   18 (27)  4 (17.4)  14 (35)   
LDL-C (mg/dl)         
≥100   45 (72.6)  16 (69.6)  29 (74.4)  0.685 
<100   18 (27.4)  8 (30.4)  10 (25.6)   
IR= insulin-resistant; NIR= noninsulin-resistant; TG= triglycerides; TC=Total cholesterol; HDL-
C=High-density lipoprotein cholesterol; LDL-C=Low-density lipoprotein cholesterol 
 
The mean of lipid profile is presented in 
Figure 1. Overall, the mean of TG was higher 
and the mean of HDL-C was lower in the IR 
than the NIR group. However, only the mean 
of HDL-C was statistically significant 
(41.78±7.54  mg/dl in the IR vs. 47.25±8.38 
mg/dl in the NIR group, Figure 1; P=0.012). 
Frequency of lipid abnormalities in the whole 
PCOS patients and also between the IR and 
NIR groups is presented in Table 2. 
For further analysis, lipid profile, fasting in-
sulin, and HOMA-IR were compared between 
the two subgroups of overweight and obese 
PCOS patients. Although TG, TC, and LDL-
C were higher and HDL-C was lower in the 
IR than the NIR group (Fig. 1), no significant 
difference was observed in lipid profile be-
tween these two subgroups of the patients (da-
ta not shown). However, fasting insulin 
(18.42±9.61  vs.  13.43±4.42;  P=0.008)  and 
HOMA-IR (3.86±1.92 µU/mL vs. 3.04±1.07 
µU/mL; P=0.036) were significantly higher in 
obese PCOS patients than overweight PCOS 
women. For the whole PCOS patients, BMI 
showed a significant correlation with TC only 
after adjustment for age and DHEAS level as 
confounders. Waist circumference significantly 
correlated with TC (r=0.32, P=0.015) and 
LDL-C (r=0.28; P=0.030); however, it became 
non-significant after controlling for the con-
founders. Hip circumference was significantly 
associated with TG (r=0.26; P=0.044). It was 
also significantly correlated with TC (r=0.27; 
P=0.036) and LDL-C (r=0.24; P=0.049) (Fig. 
2). Nevertheless, only the association of hip 
circumference with TG remained significant 
after adjustment (r=0.31; P=0.021). In addi-
tion, WHtR correlated significantly with TC 
(r=0.37;  P=0.004) and LDL-C (r=0.33; 
P=0.011) (Fig. 2). The results of partial corre-
lation also showed a significant association of 
WHtR with TC (r=0.33; P=0.016) as well as 
with LDL-C (r=0.30; P=0.034). 
We also tried to find such correlations in 
subgroups of PCOS population (i.e. the IR 
and the NIR groups) (Table 3 and 4). TC as 
well as LDL-C showed significant correlations 
with all of the anthropometric indices except 
for WHR in the NIR group (Table3). After 
controlling for the effects of age and DHEAS, 
only the associations of BMI and hip circum-
ference with TC and LDL-C remained signifi-
cant in the NIR group (P<0.05) (Table4). 
*Independent samples t-test, IR= insulin-resistant; NIR= noninsulin-resistant; HOMA-IR= homeostasis model of insu-
lin resistance; BMI= body mass index; WC=waist circumference;  HC= hip circumference; WHR=waist to hip ratio; 
waist to height ratio 
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Fig. 2: Correlation coefficients of hip circumference and WHtR with TC and LDL-C in the whole PCOS pa-
tients 
 
Table 3: Pearson correlation coefficients for the associations between lipid profile and anthropometric 
indices in IR and NIR PCOS women 
* P-value<0.05/** P-value<0.01 
 
Table 4: Partial correlation coefficients for the association between lipid profile and anthropometric indi-
ces in IR and NIR PCOS women (controlling for the effects of age and DHEAS) 
* P-value<0.05 
 
Variable 
IR group (n=23)  NIR group (n=40) 
TG  TC  HDL-C  LDL-C  TG  TC  HDL-C  LDL-C 
BMI (kg/m2)  0.09  -0.03  0.05  -0.09  0.12  0.38*  0.01  0.40* 
WC (cm)  0.38  0.12  -0.22  0.01  0.07  0.42**  0.09  0.42* 
HC (cm)  0.40  -0.09  -0.26  -0.23  0.15  0.43**  -0.02  0.43** 
WHR  0.14  0.35  -0.02  0.36  -0.12  0.03  0.21  0.03 
WHtR  0.23  0.24  0.02  0.17  0.15  0.44**  0.11  0.41* 
 
Variable 
IR group (n=23)  NIR group (n=40) 
TG  TC  HDL-C  LDL-C  TG  TC  HDL-C  LDL-C 
BMI (kg/m2)  0.03  -
0.02 
0.08  -0.05  0.30  0.39*  -0.01  0.33* 
WC (cm)  0.38  0.12  -0.32  0.04  0.09  0.26  0.04  0.25 
HC (cm)  0.39  -
0.13 
-0.34  -0.26  0.22  0.39*  -0.10  0.39* 
WHR  0.11  0.38  -0.07  0.42  -0.12  -0.27  0.28  -0.29 
WHtR  0.19  0.28  -0.03  0.25  0.20  0.32  0.02  0.27 Health Promotion Perspectives, Vol. 3, No. 2, 2013; P: 206-216 
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Discussion  
 
The present study was aimed to investi-
gate the relation of anthropometric indices 
and insulin resistance with lipid profile in 
overweight or obese women with PCOS. 
The prevalence of IR was 36.5% among the 
PCOS patients. According to our findings, 
IR is at least, partly, related to obesity and 
not attributed solely to PCOS. Since in our 
study, insulin concentration and HOMA-IR 
were significantly higher in the obese PCOS 
patients compared to the overweight wom-
en. On the other hand, the mean BMI 
(though non-significantly) was higher in the 
IR than NIR patients, a finding which is 
consistent with previous studies
36-38. In fact, 
as mentioned earlier, abdominal obesity can 
result in higher insulin concentration
39; and 
the resultant hyperinsulinemia may encour-
age further obesity
40. As IR occurs in obese 
as well as lean subjects with PCOS,  it is 
seemingly independent of obesity
41-43. None-
theless, any degree of obesity is liable to trig-
ger reduced insulin sensitivity.  
Our results also showed that among lipid 
profile, only HDL-C was significantly lower 
in the IR group (Fig. 1). The finding about 
HDL-C is in line with prior studies
36-37 ,44-46. 
In the study conducted by Rabinson et al.
 45, 
the authors suggested that low HDL-C was 
associated with insulin sensitivity rather than 
BMI. They concluded that PCOS was ac-
companied by biochemical risk factors for 
premature vascular disease, which could not 
be explained by obesity alone. In our study, 
elevated LDL-C level was not found in the 
insulin-resistant patients like the study by 
Kalra et al.
 37 who compared lipid profile be-
tween insulin-resistant and non insulin-
resistant PCOS groups. In another study, no 
significant correlation was observed between 
HOMA-IR and LDL-C
44. However, in a 
large study of non-Hispanic white women
4, 
in which obese PCOS patients were com-
pared to obese controls, elevations in LDL-
C levels were the dominant lipid abnormality 
in women with PCOS, independent of obe-
sity. Of course, the level of HDL-C was also 
elevated in the obese PCOS women; how-
ever, the characteristic dyslipidemia of IR 
was not observed.  
In our study, though obesity was more 
common in the IR group (P=0.038), how-
ever, the two groups were similarly obese. 
Obesity has an important impact on lipid 
profile. Dyslipidemia of obesity is charac-
terized by increased TG, low levels of HDL-
C, increased subfractions of small, dense 
LDL, and increased levels of apolipoprotein 
B-100
47-48.  
Around 50% of PCOS patients are over-
weight or obese with accumulation of ab-
dominal fat
49. Cibula et al. showed the effect 
of obesity on lipid profile and hyperlipopro-
teinemia  in PCOS women
7. Researchers 
demonstrated that lipid and lipoproteins did 
not differ in obese, overweight and non ob-
ese PCOS patients compared with control 
subjects, while HDL-C was decreased in ob-
ese PCOS and obese control women
50-51. In 
non obese patients with PCOS, serum TG 
levels correlated with visceral fat and prepe-
ritoneal fat thickness. The authors con-
cluded that intra-abdominal, preperitoneal, 
and visceral fat accumulation may contribute 
to the development of lipid metabolism dis-
orders in non obese women with PCOS
52.  
Among anthropometric measures, WHtR 
showed the strongest correlation with lipid 
profile components (r=0.37; P=0.004 for 
TC) and (r=0.33; P=0.011 for LDL-C) com-
pared with BMI, WC, and HC in the whole 
patients (Fig. 2). Costa et al. indicated that 
WHtR and WC are more accurate than 
WHR to predict metabolic syndrome in Bra-
zilian PCOS women
53. Jiang et al. showed 
that BMI alone is not a significant contrib-
utory factor causing impaired glucose toler-
ance in PCOS women. WHtR is one more 
significant and predictive index for the oc-
currence of abnormal glucose tolerance
54. In 
a research on the anthropometric indices of 
visceral obesity and cardiovascular risk fac-
tors among PCOS patients, both WHtR and 
WC but not WHR showed to be good 
markers of adverse metabolic profile in 
women with PCOS
55. The results of a meta-
analysis support the superiority of measures 
of centralized obesity, especially WHtR, over Saghafi-Aslet al.: Lipid Profile In Relation To Anthropometric Indices… 
 
213 
BMI, for detecting cardiovascular risk fac-
tors in both men and women
56. WHtR and 
WC are strongly associated with cardiovas-
cular risk factors than WHR
55. BMI, WHR 
and WHtR significantly correlated with fast-
ing blood sugar (FBS), TC and TG using 
partial correlation test. Amongst, the highest 
correlation was observed for WHtR than 
BMI and WHR
57. WHtR was a valuable obe-
sity index for predicting lipidemia, diabetes, 
and hypertension
57. 
In our unpublished data on this popula-
tion, serum DHEAS level correlated signifi-
cantly with some of the anthropometric 
measures like a previous study
55. Therefore, 
we controlled the effects of DHEAS level, 
too. After removing the effects of con-
founders (age and serum DHEAS level), 
WHtR again showed the strongest associa-
tion with TC (r=0.33; P=0.016) and LDL-C 
(r=0.30;  P=0.034) in the overall patients. 
When divided the patients into IR and NIR 
groups, only the correlation of BMI and hip 
circumference with TC and LDL-C was sig-
nificant in the NIR group. Hip circumfer-
ence in women is a stronger independent 
predictive risk factor for total death and de-
velopment of CVD or CHD than either 
BMI or waist circumference
58. Dyslipidemia 
is common in women with PCOS, mainly 
due to low HDL-C levels and BMI has a 
significant impact on this abnormality (46). 
In a study on Chinese population, general 
adiposity was the only obesity determinant 
of LDL-cholesterol
59. 
   A relatively limited sample population 
was included in the present study due to tak-
ing into account a vast number of effective 
confounders as inclusion criteria. The con-
troversies which exist in different  studies 
may result from different diagnostic criteria 
used for PCOS, inclusion of women with 
different BMIs, and probable use of proges-
tin for menstrual induction preceding the 
study. However, in the present investigation, 
diagnosis of PCOS was based on the Rot-
terdom criteria, widely used in most re-
searches. Moreover, only overweight or ob-
ese patients at a limited age range (i.e.17-37 
years) were recruited. Finally, no hormonal 
treatment (i.e. progestin) was used for men-
strual induction before the study.  
 
Conclusion 
 
 Our study suggests that anthropometric 
characteristics (especially BMI and hip cir-
cumference) are more important parameters 
correlated to lipid profile than IR in PCOS 
patients, approving the importance of early 
treatment of obesity to prevent further car-
diometabolic complications in the future. 
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